| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Diagnostic Techniques | 9 | 2020 | 47 | 3.070 |
Why?
|
| Polymerase Chain Reaction | 20 | 2020 | 492 | 2.840 |
Why?
|
| RNA, Viral | 14 | 2014 | 93 | 1.690 |
Why?
|
| HIV-1 | 8 | 2020 | 177 | 1.600 |
Why?
|
| Blood Culture | 3 | 2020 | 15 | 1.440 |
Why?
|
| Virology | 6 | 2011 | 11 | 1.420 |
Why?
|
| Bacteremia | 5 | 2020 | 155 | 1.410 |
Why?
|
| Enterovirus Infections | 4 | 2011 | 6 | 1.340 |
Why?
|
| Hepacivirus | 9 | 2005 | 90 | 1.270 |
Why?
|
| Microbial Sensitivity Tests | 12 | 2021 | 226 | 1.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 710 | 1.100 |
Why?
|
| Enterovirus | 4 | 2017 | 12 | 1.090 |
Why?
|
| Meningitis, Viral | 3 | 2011 | 5 | 1.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 5 | 2014 | 21 | 1.000 |
Why?
|
| Virus Diseases | 4 | 2014 | 31 | 0.960 |
Why?
|
| Sensitivity and Specificity | 24 | 2022 | 1753 | 0.950 |
Why?
|
| Anti-Bacterial Agents | 11 | 2018 | 1026 | 0.890 |
Why?
|
| Viral Load | 9 | 2014 | 127 | 0.880 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 209 | 0.840 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 5 | 0.730 |
Why?
|
| Humans | 88 | 2022 | 68618 | 0.710 |
Why?
|
| Pandemics | 2 | 2022 | 352 | 0.710 |
Why?
|
| Respiratory Tract Infections | 5 | 2018 | 91 | 0.700 |
Why?
|
| Bacteriological Techniques | 5 | 2013 | 49 | 0.670 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.650 |
Why?
|
| HIV Infections | 5 | 2020 | 791 | 0.640 |
Why?
|
| Diarrhea | 3 | 2013 | 63 | 0.630 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2008 | 54 | 0.620 |
Why?
|
| Drug Utilization | 2 | 2016 | 119 | 0.610 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.580 |
Why?
|
| Feces | 4 | 2013 | 88 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.580 |
Why?
|
| Legionella | 5 | 2012 | 9 | 0.570 |
Why?
|
| Legionnaires' Disease | 4 | 2012 | 11 | 0.570 |
Why?
|
| Microbiological Techniques | 3 | 2012 | 9 | 0.570 |
Why?
|
| Influenza B virus | 1 | 2016 | 2 | 0.560 |
Why?
|
| Candidemia | 1 | 2016 | 2 | 0.560 |
Why?
|
| Influenza A virus | 1 | 2016 | 13 | 0.560 |
Why?
|
| Mutation | 2 | 2016 | 1213 | 0.550 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 24 | 0.540 |
Why?
|
| Thalidomide | 1 | 2016 | 24 | 0.540 |
Why?
|
| Communicable Diseases | 2 | 2012 | 50 | 0.540 |
Why?
|
| Viruses | 4 | 2009 | 14 | 0.530 |
Why?
|
| Bacterial Infections | 3 | 2018 | 163 | 0.530 |
Why?
|
| Influenza, Human | 1 | 2016 | 79 | 0.520 |
Why?
|
| Immunologic Factors | 1 | 2016 | 87 | 0.510 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 115 | 0.500 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2006 | 61 | 0.490 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2014 | 44 | 0.480 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 17 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.480 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 4848 | 0.460 |
Why?
|
| HIV Antibodies | 2 | 2010 | 28 | 0.450 |
Why?
|
| Leukorrhea | 1 | 2013 | 6 | 0.450 |
Why?
|
| DNA, Viral | 4 | 2017 | 114 | 0.450 |
Why?
|
| Trichomonas vaginalis | 1 | 2013 | 22 | 0.440 |
Why?
|
| Trichomonas Vaginitis | 1 | 2013 | 25 | 0.430 |
Why?
|
| HIV Seropositivity | 2 | 2010 | 66 | 0.430 |
Why?
|
| Clostridium Infections | 1 | 2013 | 52 | 0.430 |
Why?
|
| Transplantation | 1 | 2012 | 23 | 0.420 |
Why?
|
| Hepatitis C | 5 | 2005 | 114 | 0.420 |
Why?
|
| Pathologists | 3 | 2021 | 10 | 0.420 |
Why?
|
| Diagnostic Services | 1 | 2012 | 1 | 0.410 |
Why?
|
| Penicillin Resistance | 3 | 2005 | 12 | 0.410 |
Why?
|
| Adult | 24 | 2020 | 21403 | 0.400 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 194 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 300 | 0.390 |
Why?
|
| Herpesvirus 4, Human | 2 | 2008 | 30 | 0.390 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2008 | 24 | 0.390 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 2077 | 0.390 |
Why?
|
| AIDS Vaccines | 1 | 2010 | 7 | 0.370 |
Why?
|
| Hepatitis C, Chronic | 2 | 2003 | 86 | 0.370 |
Why?
|
| Middle Aged | 18 | 2020 | 21147 | 0.370 |
Why?
|
| Young Adult | 9 | 2020 | 5717 | 0.360 |
Why?
|
| Aged | 13 | 2020 | 14862 | 0.350 |
Why?
|
| Culture Media | 6 | 1995 | 155 | 0.340 |
Why?
|
| Oxacillin | 2 | 2005 | 4 | 0.330 |
Why?
|
| Female | 24 | 2017 | 38074 | 0.330 |
Why?
|
| Klebsiella pneumoniae | 1 | 2008 | 18 | 0.330 |
Why?
|
| beta-Lactamases | 1 | 2008 | 33 | 0.320 |
Why?
|
| Infant, Newborn | 6 | 2020 | 2455 | 0.310 |
Why?
|
| Bacterial Proteins | 2 | 2008 | 245 | 0.310 |
Why?
|
| Staphylococcus aureus | 2 | 2005 | 175 | 0.300 |
Why?
|
| Pneumonia | 1 | 2008 | 110 | 0.300 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2008 | 60 | 0.290 |
Why?
|
| 5' Untranslated Regions | 2 | 2007 | 16 | 0.290 |
Why?
|
| Adolescent | 8 | 2020 | 8912 | 0.280 |
Why?
|
| Polyomavirus Infections | 1 | 2006 | 17 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 4 | 2012 | 208 | 0.280 |
Why?
|
| Tumor Virus Infections | 1 | 2006 | 32 | 0.280 |
Why?
|
| Viremia | 5 | 1999 | 13 | 0.270 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 11 | 0.270 |
Why?
|
| Male | 25 | 2017 | 37321 | 0.270 |
Why?
|
| Time Factors | 8 | 2016 | 4655 | 0.270 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 159 | 0.260 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2005 | 15 | 0.260 |
Why?
|
| Infant | 6 | 2017 | 2891 | 0.260 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 1997 | 116 | 0.260 |
Why?
|
| Blood | 3 | 2007 | 40 | 0.250 |
Why?
|
| Child, Preschool | 6 | 2017 | 3187 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 149 | 0.250 |
Why?
|
| False Positive Reactions | 4 | 2014 | 95 | 0.250 |
Why?
|
| Beauty Culture | 1 | 2004 | 1 | 0.240 |
Why?
|
| Furunculosis | 1 | 2004 | 1 | 0.240 |
Why?
|
| Nails | 1 | 2004 | 15 | 0.240 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2004 | 2 | 0.240 |
Why?
|
| Mycobacterium | 1 | 2004 | 12 | 0.240 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2003 | 95 | 0.240 |
Why?
|
| Genotype | 5 | 2006 | 786 | 0.240 |
Why?
|
| Mycobacterium Infections | 1 | 2004 | 13 | 0.230 |
Why?
|
| United States | 8 | 2022 | 7367 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2006 | 307 | 0.230 |
Why?
|
| Evaluation Studies as Topic | 8 | 1998 | 219 | 0.230 |
Why?
|
| Chlamydia trachomatis | 1 | 2003 | 26 | 0.220 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 110 | 0.220 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2003 | 35 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2003 | 41 | 0.220 |
Why?
|
| Nocardia | 2 | 1993 | 6 | 0.220 |
Why?
|
| Gonorrhea | 1 | 2003 | 50 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 627 | 0.220 |
Why?
|
| Mycobacterium tuberculosis | 3 | 1995 | 103 | 0.220 |
Why?
|
| Enterococcus | 2 | 2020 | 29 | 0.210 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 54 | 0.200 |
Why?
|
| Prevalence | 3 | 2016 | 1619 | 0.190 |
Why?
|
| Sepsis | 2 | 2018 | 233 | 0.190 |
Why?
|
| Encephalitis | 2 | 2003 | 43 | 0.190 |
Why?
|
| Enterococcus faecalis | 2 | 2008 | 6 | 0.190 |
Why?
|
| Child | 6 | 2017 | 6405 | 0.190 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 481 | 0.180 |
Why?
|
| Interferon-alpha | 1 | 2000 | 46 | 0.180 |
Why?
|
| Gram-Positive Bacteria | 1 | 2020 | 23 | 0.180 |
Why?
|
| Candidiasis | 2 | 1997 | 39 | 0.180 |
Why?
|
| Staphylococcus | 1 | 2020 | 29 | 0.180 |
Why?
|
| Microfluidics | 1 | 2020 | 22 | 0.180 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 1997 | 35 | 0.170 |
Why?
|
| Vancomycin | 2 | 1997 | 60 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 2 | 2010 | 23 | 0.160 |
Why?
|
| Leadership | 1 | 2020 | 136 | 0.160 |
Why?
|
| Algorithms | 3 | 2020 | 1196 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2000 | 211 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 58 | 0.160 |
Why?
|
| Molecular Probe Techniques | 1 | 1998 | 7 | 0.160 |
Why?
|
| Antifungal Agents | 2 | 2007 | 108 | 0.150 |
Why?
|
| Cross Infection | 3 | 2009 | 195 | 0.150 |
Why?
|
| DNA, Bacterial | 4 | 2012 | 150 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2020 | 403 | 0.150 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 306 | 0.150 |
Why?
|
| Gene Amplification | 3 | 2004 | 71 | 0.150 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 11 | 0.140 |
Why?
|
| Amphotericin B | 1 | 1997 | 26 | 0.140 |
Why?
|
| Fluconazole | 1 | 1997 | 26 | 0.140 |
Why?
|
| Treponema pallidum | 1 | 2016 | 5 | 0.140 |
Why?
|
| Candida albicans | 1 | 1997 | 39 | 0.140 |
Why?
|
| Gram-Positive Asporogenous Rods | 1 | 1996 | 1 | 0.140 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2016 | 19 | 0.140 |
Why?
|
| Syphilis | 1 | 2016 | 15 | 0.140 |
Why?
|
| False Negative Reactions | 4 | 2016 | 63 | 0.140 |
Why?
|
| Vibrio Infections | 1 | 1996 | 3 | 0.140 |
Why?
|
| Mitosporic Fungi | 1 | 1996 | 2 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 70 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 41 | 0.140 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 90 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 1996 | 33 | 0.130 |
Why?
|
| Quality Control | 4 | 2021 | 81 | 0.130 |
Why?
|
| Immunoassay | 2 | 2018 | 64 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 196 | 0.130 |
Why?
|
| Mycoses | 1 | 1996 | 60 | 0.130 |
Why?
|
| Rhinovirus | 3 | 2017 | 15 | 0.130 |
Why?
|
| Streptococcus pneumoniae | 1 | 1995 | 32 | 0.130 |
Why?
|
| Poloxalene | 1 | 1995 | 2 | 0.130 |
Why?
|
| DNA | 1 | 1998 | 597 | 0.120 |
Why?
|
| Mycobacterium avium Complex | 1 | 1995 | 16 | 0.120 |
Why?
|
| Sputum | 2 | 1993 | 51 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2013 | 618 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2014 | 64 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 1995 | 69 | 0.120 |
Why?
|
| Fungi | 2 | 2020 | 27 | 0.120 |
Why?
|
| Virus Cultivation | 3 | 2009 | 3 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2016 | 3705 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1664 | 0.110 |
Why?
|
| Parasitology | 1 | 2013 | 4 | 0.110 |
Why?
|
| Gentamicins | 2 | 1993 | 68 | 0.110 |
Why?
|
| Exudates and Transudates | 1 | 2013 | 25 | 0.110 |
Why?
|
| Monitoring, Physiologic | 2 | 2000 | 219 | 0.110 |
Why?
|
| Microscopy | 1 | 2013 | 64 | 0.110 |
Why?
|
| Diagnostic Errors | 2 | 2008 | 100 | 0.110 |
Why?
|
| Nocardia asteroides | 1 | 1992 | 4 | 0.110 |
Why?
|
| DNA, Ribosomal | 1 | 2012 | 59 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 85 | 0.100 |
Why?
|
| Molecular Sequence Data | 3 | 2005 | 1447 | 0.100 |
Why?
|
| United States Food and Drug Administration | 2 | 2021 | 131 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2004 | 737 | 0.100 |
Why?
|
| Anesthesia, Closed-Circuit | 1 | 1991 | 1 | 0.100 |
Why?
|
| Water Microbiology | 3 | 2009 | 24 | 0.090 |
Why?
|
| Prognosis | 2 | 2014 | 2093 | 0.090 |
Why?
|
| Anesthesia, General | 1 | 1991 | 86 | 0.090 |
Why?
|
| Cord Factors | 1 | 1990 | 1 | 0.090 |
Why?
|
| Pregnancy | 2 | 2014 | 2334 | 0.090 |
Why?
|
| Glycolipids | 1 | 1990 | 20 | 0.090 |
Why?
|
| Bacteria | 2 | 2008 | 193 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 454 | 0.080 |
Why?
|
| Tuberculosis | 1 | 1990 | 77 | 0.080 |
Why?
|
| Fluorescence | 2 | 2004 | 104 | 0.080 |
Why?
|
| Legionella pneumophila | 1 | 2009 | 6 | 0.080 |
Why?
|
| Ice | 1 | 2009 | 13 | 0.080 |
Why?
|
| Latex Fixation Tests | 2 | 2005 | 4 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2008 | 44 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 2009 | 38 | 0.080 |
Why?
|
| Klebsiella Infections | 1 | 2008 | 13 | 0.080 |
Why?
|
| Medical Laboratory Personnel | 1 | 2008 | 1 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 37 | 0.080 |
Why?
|
| Uncertainty | 1 | 2008 | 31 | 0.080 |
Why?
|
| Antibodies, Heterophile | 1 | 2008 | 11 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 83 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2000 | 193 | 0.080 |
Why?
|
| Candida | 2 | 1999 | 15 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 954 | 0.080 |
Why?
|
| Vibrionaceae | 1 | 1988 | 1 | 0.080 |
Why?
|
| Proctitis | 1 | 1988 | 2 | 0.080 |
Why?
|
| DNA, Fungal | 2 | 1999 | 20 | 0.080 |
Why?
|
| Daptomycin | 1 | 2008 | 11 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2009 | 117 | 0.080 |
Why?
|
| Patient Care | 1 | 2008 | 61 | 0.080 |
Why?
|
| Endocarditis, Bacterial | 1 | 2008 | 32 | 0.080 |
Why?
|
| Specimen Handling | 2 | 2008 | 47 | 0.080 |
Why?
|
| Yersinia | 1 | 1987 | 2 | 0.070 |
Why?
|
| Yersinia Infections | 1 | 1987 | 2 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2007 | 21 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2008 | 308 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 177 | 0.070 |
Why?
|
| Zygomycosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Fungemia | 2 | 1997 | 13 | 0.070 |
Why?
|
| Dermatomycoses | 1 | 2007 | 17 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 98 | 0.070 |
Why?
|
| Meningitis | 1 | 2007 | 23 | 0.070 |
Why?
|
| Triazoles | 1 | 2007 | 43 | 0.070 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 191 | 0.070 |
Why?
|
| BK Virus | 1 | 2006 | 17 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 3 | 1997 | 70 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2006 | 5 | 0.070 |
Why?
|
| Transition Temperature | 1 | 2006 | 9 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2016 | 7029 | 0.070 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1986 | 21 | 0.070 |
Why?
|
| Alleles | 2 | 2006 | 386 | 0.070 |
Why?
|
| Enterobacteriaceae | 1 | 1985 | 29 | 0.070 |
Why?
|
| Viral Proteins | 1 | 2007 | 150 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2005 | 35 | 0.060 |
Why?
|
| Warfarin | 1 | 2006 | 93 | 0.060 |
Why?
|
| Epitopes | 1 | 1986 | 146 | 0.060 |
Why?
|
| Base Sequence | 3 | 2003 | 1015 | 0.060 |
Why?
|
| Resins, Plant | 1 | 1984 | 4 | 0.060 |
Why?
|
| Animals | 6 | 2003 | 20881 | 0.060 |
Why?
|
| Serotyping | 3 | 2009 | 16 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2005 | 92 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 504 | 0.060 |
Why?
|
| Hydrotherapy | 1 | 2004 | 1 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2004 | 34 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2004 | 23 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2004 | 25 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1745 | 0.060 |
Why?
|
| Acanthamoeba | 1 | 2003 | 2 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 10 | 0.060 |
Why?
|
| Amebiasis | 1 | 2003 | 6 | 0.060 |
Why?
|
| Tracheostomy | 1 | 2003 | 31 | 0.060 |
Why?
|
| Urine | 1 | 2003 | 47 | 0.060 |
Why?
|
| Coronavirus | 2 | 2017 | 16 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2006 | 356 | 0.060 |
Why?
|
| Automation | 1 | 2003 | 45 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 16 | 0.050 |
Why?
|
| Plasmids | 1 | 1984 | 258 | 0.050 |
Why?
|
| Charcoal | 2 | 1993 | 37 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2008 | 711 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2008 | 164 | 0.050 |
Why?
|
| DNA Probes | 2 | 1999 | 57 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 46 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 507 | 0.050 |
Why?
|
| Wound Healing | 1 | 2003 | 260 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2000 | 772 | 0.050 |
Why?
|
| Plasma | 2 | 2006 | 58 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2000 | 7 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 20 | 0.050 |
Why?
|
| Species Specificity | 4 | 1999 | 303 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.050 |
Why?
|
| Public Health | 1 | 2022 | 201 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 455 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 144 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7277 | 0.040 |
Why?
|
| Biomarkers | 3 | 2018 | 1593 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1999 | 98 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2020 | 202 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 567 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 11 | 0.040 |
Why?
|
| DNA Primers | 2 | 1997 | 302 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 742 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 33 | 0.040 |
Why?
|
| Flaviviridae | 1 | 1998 | 2 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 135 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 1998 | 23 | 0.040 |
Why?
|
| Carbon-Oxygen Ligases | 1 | 1997 | 1 | 0.040 |
Why?
|
| Ligases | 1 | 1997 | 6 | 0.040 |
Why?
|
| Trypanosoma brucei brucei | 1 | 1998 | 20 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 109 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 1998 | 63 | 0.040 |
Why?
|
| Radiometry | 2 | 1990 | 64 | 0.040 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 11 | 0.040 |
Why?
|
| Forensic Pathology | 1 | 2017 | 19 | 0.040 |
Why?
|
| Flucytosine | 1 | 1997 | 5 | 0.040 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2016 | 6 | 0.040 |
Why?
|
| Virulence | 1 | 1997 | 51 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 56 | 0.040 |
Why?
|
| Cellulitis | 1 | 1996 | 13 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 1996 | 19 | 0.030 |
Why?
|
| Eels | 1 | 1996 | 2 | 0.030 |
Why?
|
| Vibrio | 1 | 1996 | 14 | 0.030 |
Why?
|
| Food Microbiology | 1 | 1996 | 24 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 295 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 1995 | 3 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1996 | 242 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1995 | 30 | 0.030 |
Why?
|
| Necrosis | 1 | 1996 | 239 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1995 | 27 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1995 | 32 | 0.030 |
Why?
|
| Leukocytes | 1 | 1995 | 99 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2358 | 0.030 |
Why?
|
| Rifampin | 1 | 1995 | 45 | 0.030 |
Why?
|
| Campylobacter | 1 | 1994 | 5 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1995 | 260 | 0.030 |
Why?
|
| South Carolina | 1 | 2020 | 2752 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 277 | 0.030 |
Why?
|
| Buffers | 1 | 1993 | 31 | 0.030 |
Why?
|
| Streptomycin | 1 | 1993 | 12 | 0.030 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1993 | 25 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1993 | 78 | 0.030 |
Why?
|
| Yeast, Dried | 1 | 1992 | 1 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1994 | 368 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1994 | 562 | 0.020 |
Why?
|
| Micrococcus | 1 | 1991 | 4 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1993 | 156 | 0.020 |
Why?
|
| Filtration | 1 | 1991 | 61 | 0.020 |
Why?
|
| MEDLINE | 2 | 2000 | 9 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 193 | 0.020 |
Why?
|
| Liver Function Tests | 2 | 2000 | 114 | 0.020 |
Why?
|
| Cost Control | 1 | 1989 | 34 | 0.020 |
Why?
|
| Equipment Design | 1 | 1991 | 500 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2009 | 7 | 0.020 |
Why?
|
| Bronchoscopes | 1 | 2009 | 9 | 0.020 |
Why?
|
| Metapneumovirus | 1 | 2009 | 1 | 0.020 |
Why?
|
| Acute Disease | 2 | 2000 | 658 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 24 | 0.020 |
Why?
|
| Time | 1 | 2008 | 57 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 61 | 0.020 |
Why?
|
| Bisexuality | 1 | 1988 | 18 | 0.020 |
Why?
|
| Coagulase | 1 | 1986 | 14 | 0.020 |
Why?
|
| Staphylococcal Protein A | 1 | 1986 | 15 | 0.020 |
Why?
|
| Immunodiffusion | 1 | 1986 | 19 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 1986 | 511 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 1988 | 222 | 0.020 |
Why?
|
| Aortic Valve | 1 | 1988 | 249 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 37 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2000 | 1330 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 272 | 0.020 |
Why?
|
| Hepatitis C Antibodies | 1 | 2005 | 19 | 0.020 |
Why?
|
| Genes, Bacterial | 1 | 1985 | 40 | 0.020 |
Why?
|
| Enzymes | 1 | 1985 | 25 | 0.020 |
Why?
|
| Genes | 1 | 1985 | 86 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 137 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 780 | 0.020 |
Why?
|
| Blood Cells | 1 | 1984 | 27 | 0.020 |
Why?
|
| Mice | 1 | 1997 | 8474 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2006 | 110 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 2003 | 6 | 0.010 |
Why?
|
| Tracheal Stenosis | 1 | 2003 | 21 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2003 | 38 | 0.010 |
Why?
|
| Adsorption | 1 | 1984 | 225 | 0.010 |
Why?
|
| Cicatrix | 1 | 2003 | 60 | 0.010 |
Why?
|
| Peptide Library | 1 | 2003 | 16 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 167 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 357 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1046 | 0.010 |
Why?
|
| Leucyl Aminopeptidase | 1 | 1982 | 1 | 0.010 |
Why?
|
| Esterases | 1 | 1982 | 9 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1982 | 36 | 0.010 |
Why?
|
| Methods | 1 | 1982 | 156 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1982 | 71 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 852 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 694 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 1266 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1984 | 2673 | 0.010 |
Why?
|
| Phosphodiesterase I | 1 | 1999 | 3 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1999 | 22 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 1864 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 1615 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 3259 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 778 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 5731 | 0.010 |
Why?
|
| Phenotype | 1 | 1997 | 947 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1985 | 220 | 0.000 |
Why?
|